Neuromuscular Junction: How Nerves Signal Muscles to Contract

The neuromuscular junction (NMJ) is the specialized chemical synapse between a motor neuron and a skeletal muscle fiber. It translates neural electrical signals into mechanical force.

Step-by-Step Transmission

  1. Action Potential Arrival: Depolarization reaches presynaptic terminal.
  2. Voltage-Gated Ca²⁺ Channels Open: Ca²⁺ influx triggers vesicle fusion.
  3. Acetylcholine (ACh) Release: ~150–200 vesicles (quanta) released by exocytosis into synaptic cleft (50 nm).
  4. ACh Diffusion & Binding: Binds to nicotinic ACh receptors (nAChR) on motor endplate (folded postsynaptic membrane).
  5. Ion Channel Opening: Each nAChR = 5 subunits (2α, β, δ, ε/γ). 2 ACh molecules bind → conformational change → Na⁺ influx / K⁺ efflux.
  6. Endplate Potential (EPP): Local depolarization (~+50 mV). Always suprathreshold (safety factor ~3–4).
  7. Action Potential Propagation: EPP spreads → opens voltage-gated Na⁺ channels on sarcolemma → muscle AP → T-tubules → SR Ca²⁺ release → contraction.
  8. Termination: Acetylcholinesterase (AChE) hydrolyzes ACh → acetate + choline. Choline reuptaken for resynthesis.

Key Structural Features

  • Motor Unit: One α-motor neuron + all muscle fibers it innervates (few in eye, thousands in gastrocnemius).
  • Endplate: Specialized postsynaptic region with junctional folds (↑ surface area, ↑ nAChR density ~10,000/µm²).
  • Basal Lamina: Contains AChE (anchored by collagen Q).
  • Schwann Cell Cap: Covers terminal; modulates development/repair.

Clinical Correlates

  • Myasthenia Gravis: Autoantibodies vs nAChR (85%) or MuSK/LRP4 → ↓ receptors → fatigable weakness. Tx: AChE inhibitors, immunosuppression, thymectomy.
  • Lambert-Eaton (LEMS): Autoantibodies vs presynaptic VGCC → ↓ ACh release. Proximal weakness, autonomic signs. Associated with SCLC.
  • Botulism: BoNT cleaves SNARE proteins → blocks vesicle fusion. Descending paralysis.
  • Organophosphate Poisoning: Irreversible AChE inhibition → cholinergic crisis (SLUDGE). Tx: atropine, pralidoxime.
  • Congenital Myasthenic Syndromes: Genetic defects in NMJ proteins (CHRNE, RAPSN, DOK7, COLQ).

Pharmacology

  • Non-depolarizing NMBAs (rocuronium, vecuronium): Competitive nAChR antagonists → paralysis (surgery, ICU).
  • Depolarizing NMBA (succinylcholine): Persistent depolarization → phase I block → desensitization.
  • AChE Inhibitors (pyridostigmine, neostigmine): Prolong ACh action → enhance transmission (MG, reversal of NMBAs).

The NMJ is a high-fidelity, high-safety-factor synapse — designed for reliability. Its dysfunction causes profound weakness but also offers precise therapeutic targets.

Brain & Nervous System - Related Articles